Takeda reports interim results from Phase III trial of cTTP therapy

Takeda reports interim results from Phase III trial of cTTP therapy

Source: 
Clinical Trials Arena
snippet: 

Takeda has reported favourable interim results from a Phase III clinical trial of TAK-755 (recombinant ADAMTS13) for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura (cTTP).